Telmisartan — $0 on Listed Strengths

Other medications in Heart & Cardiovascular

• Ticagrelor
• Torsemide
• Trandolapril
• Treprostinil
• Triamterene
• Valsartan
• Verapamil
• Verapamil IV

About Telmisartan

Telmisartan is a widely prescribed medication used to manage high blood pressure and reduce cardiovascular risk. For many, maintaining consistent access to essential prescriptions like Telmisartan is crucial for long-term health. At TheDrugClub, we understand the importance of affordability, helping our members unlock significant savings on their medications.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Telmisartan is approved for (FDA label)

Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs.

Source: Read the full FDA label on DailyMed. Label effective date: August 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Telmisartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue telmisartan tablets as soon as possible [ See Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 ) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [ See Warnings and Precautions( 5.1 ) and Use in Specific Populations ( 8.1 ) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue telmisartan tablets as soon as possible ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 )

Source: FDA prescribing information (DailyMed). Set ID: 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6. SPL document ID: 58c9dd72-33d8-2d73-e063-6294a90a9e39. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Telmisartan (FDA label)

80 mg, white to off-white, oval, uncoated tablets debossed with “513” on one side and “S” on the other side Tablets: 80 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6. SPL document ID: 58c9dd72-33d8-2d73-e063-6294a90a9e39. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Telmisartan (FDA label)

The following adverse reaction is described elsewhere in labeling: Renal dysfunction upon use with ramipril [ see Warnings and Precautions ( 5.6 ) ] Hypertension: The most common adverse events (≥1%) reported in hypertension trials are back pain, sinusitis, and diarrhea ( 6.1 ) Cardiovascular risk reduction: The serious adverse events (≥1%) reported in cardiovascular risk reduction trials were intermittent claudication and skin ulcer ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare US LLC at 1-866-257-2597, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6. SPL document ID: 58c9dd72-33d8-2d73-e063-6294a90a9e39. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Telmisartan (FDA label)

Telmisartan tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product [see Adverse Reactions ( 6.2 )]. Do not co-administer aliskiren with telmisartan tablets in patients with diabetes [see Drug Interactions ( 7 )]. Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product ( 4 ) Do not co-administer aliskiren with telmisartan tablets in patients with diabetes ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6. SPL document ID: 58c9dd72-33d8-2d73-e063-6294a90a9e39. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Telmisartan (FDA label)

Avoid fetal or neonatal exposure ( 5.1 ) Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension ( 5.2 ) Monitor carefully in patients with impaired hepatic ( 5.4 ) or renal function ( 5.5 ) Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker ( 5.6 ) 5.1 Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Source: FDA prescribing information (DailyMed). Set ID: 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6. SPL document ID: 58c9dd72-33d8-2d73-e063-6294a90a9e39. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Telmisartan (FDA label)

Aliskiren: Do not co-administer aliskiren with telmisartan in patients with diabetes. Avoid use of aliskiren with telmisartan in patients with renal impairment (GFR <60 mL/min). Digoxin: When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range. Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. Therefore, monitor serum lithium levels during concomitant use.

Source: FDA prescribing information (DailyMed). Set ID: 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6. SPL document ID: 58c9dd72-33d8-2d73-e063-6294a90a9e39. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.